Clinical Trial Update: Radotinib as 3rd or Later Line Therapy in CP-CML [Phase 2]

View source ↗

Summary

This report notes a Phase 2 clinical trial of radotinib as third- or later-line therapy for chronic phase chronic myeloid leukemia (CP-CML). The current status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Radotinib (radotinib)

Snippet

Sponsor: Ulsan University Hospital | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: UNKNOWN